NAA10

Summary

NAA10 (N-alpha-acetyltransferase 10, NatA catalytic subunit, HGNC:18704) is a protein-coding gene on chromosome Xq28, encoding N-alpha-acetyltransferase 10 (P41227). Catalytic subunit of N-terminal acetyltransferase complexes which display alpha (N-terminal) acetyltransferase activity. It is a common-essential gene (DepMap: required in 92.8% of cancer cell lines).

N-alpha-acetylation is among the most common post-translational protein modifications in eukaryotic cells. This process involves the transfer of an acetyl group from acetyl-coenzyme A to the alpha-amino group on a nascent polypeptide and is essential for normal cell function. This gene encodes an N-terminal acetyltransferase that functions as the catalytic subunit of the major amino-terminal acetyltransferase A complex. Mutations in this gene are the cause of Ogden syndrome. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 8260 — RefSeq curated summary.

At a glance

• Gene–disease (curated): NAA10-related syndrome (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 1
• Clinical variants (ClinVar): 231 total — 14 pathogenic, 14 likely-pathogenic
• Phenotypes (HPO): 216
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 92.8% of screened cell lines (common-essential)
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_003491

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18704
Approved symbol	NAA10
Name	N-alpha-acetyltransferase 10, NatA catalytic subunit
Location	Xq28
Locus type	gene with protein product
Status	Approved
Aliases	DXS707, TE2
Ensembl gene	ENSG00000102030
Ensembl biotype	protein_coding
OMIM	300013
Entrez	8260

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 11 protein_coding, 9 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000370009, ENST00000370011, ENST00000370015, ENST00000393710, ENST00000393712, ENST00000432089, ENST00000460996, ENST00000464845, ENST00000466877, ENST00000467451, ENST00000477750, ENST00000477882, ENST00000478177, ENST00000484950, ENST00000488481, ENST00000700299, ENST00000854040, ENST00000930123, ENST00000930124, ENST00000930125, ENST00000930126

RefSeq mRNA: 3 — MANE Select: NM_003491 NM_001256119, NM_001256120, NM_003491

CCDS: CCDS14737, CCDS59179

Canonical transcript exons

ENST00000464845 — 8 exons

Exon	Start	End
ENSE00001870438	153929225	153930223
ENSE00001918122	153934884	153935037
ENSE00003486656	153930763	153930847
ENSE00003505156	153932316	153932431
ENSE00003574243	153932539	153932584
ENSE00003586877	153934377	153934475
ENSE00003623423	153932071	153932115
ENSE00003659133	153933943	153934001

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 97.73.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 78.0360 / max 369.0907, expressed in 1822 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
200927	78.0360	1822
200928	4.4210	1521

Top tissues by expression

293 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.73	gold quality
apex of heart	UBERON:0002098	97.63	gold quality
lower esophagus muscularis layer	UBERON:0035833	97.40	gold quality
lower esophagus	UBERON:0013473	97.39	gold quality
cerebellar hemisphere	UBERON:0002245	97.37	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	97.33	gold quality
gastrocnemius	UBERON:0001388	97.30	gold quality
left coronary artery	UBERON:0001626	97.27	gold quality
cerebellar cortex	UBERON:0002129	97.27	gold quality
hindlimb stylopod muscle	UBERON:0004252	97.27	gold quality
adenohypophysis	UBERON:0002196	97.25	gold quality
body of uterus	UBERON:0009853	97.24	gold quality
right frontal lobe	UBERON:0002810	97.19	gold quality
lower esophagus mucosa	UBERON:0035834	97.11	gold quality
muscle layer of sigmoid colon	UBERON:0035805	97.03	gold quality
ascending aorta	UBERON:0001496	96.94	gold quality
thoracic aorta	UBERON:0001515	96.93	gold quality
left adrenal gland cortex	UBERON:0035825	96.88	gold quality
metanephros cortex	UBERON:0010533	96.86	gold quality
stromal cell of endometrium	CL:0002255	96.85	gold quality
right coronary artery	UBERON:0001625	96.84	gold quality
coronary artery	UBERON:0001621	96.83	gold quality
left adrenal gland	UBERON:0001234	96.81	gold quality
muscle of leg	UBERON:0001383	96.79	gold quality
granulocyte	CL:0000094	96.78	gold quality
left uterine tube	UBERON:0001303	96.78	gold quality
aorta	UBERON:0000947	96.74	gold quality
popliteal artery	UBERON:0002250	96.73	gold quality
tibial artery	UBERON:0007610	96.73	gold quality
right adrenal gland	UBERON:0001233	96.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.64
E-MTAB-6379	no	378.22

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HIF1A

miRNA regulators (miRDB)

4 targeting NAA10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-6865-3P	97.54	64.67	684
HSA-MIR-4286	97.20	64.37	1587
HSA-MIR-6729-3P	96.91	66.79	703

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 92.8% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 40)

• ARD1-mediated acetylation regulates and destabilizes HIF-1 alpha by directly binding to it. (PMID:12464182)
• Human Naa15 (NATH) and Naa10 (ARD1) form a stable NatA complex which associates with ribosomes and performs co-translational N-terminal acetylation; Naa15 (NATH) and Naa10 (ARD1) are cleaved during apoptosis resulting in decreased acetyltransferase activity (PMID:15496142)
• description of the human homologue of Nat1p, NATH (NAT human), as the binding partner of the hARD1 (human ARD1) protein (PMID:15496142)
• hARD1 complexes with NATH in a ribosomal associated protein-N-acetyltransferase complex. (PMID:15496142)
• Amino-terminal acetyltransferase ARD1 (hARD1) interacts with a novel motif, 658-HGVVEVD-664, in the cytoplasmic domain of beta-amyloid precursor protein. (PMID:15749829)
• ARD1 is involved in cell proliferation and in regulating a series of cellular metabolic pathways that are regulated during hypoxia response. (PMID:15755738)
• Data demonstrate that ARD1 has limited, if any, impact on the HIF-1alpha signaling pathway. (PMID:15994306)
• levels of endogenous NATH and hARD1 proteins in thyroid papillary carcinoma patients; results suggest that NATH positively affects the level of hARD1 protein both in vivo and in cell cultures (PMID:16279846)
• ARD1 specifically binds HIF-1 alpha, suggesting a putative, still unclear, connection between these proteins. (PMID:16288748)
• A human ARD1 variant ortholog (235) has weak effects on hypoxia inducible factor (HIF)-1 alpha and VEGF mRNA stability compared to mouse ARD1 ortholog 225. (PMID:16376303)
• Essential role in cell survival through protein N-alpha-acetylation. (PMID:16518407)
• Structural characterization of native hARD1 using size exclusion chromatography, circular dichroism, & fluorescence spectroscopy shows the protein consists of compact globular region comprising 2 thirds of the protein & a flexible unstructured C terminus. (PMID:16823041)
• These results indicate that ARD1(235) and ARD1(225) isoforms may have different activities and function in different subcellular compartments of mammalian cells. (PMID:17161380)
• HIF-1alpha was found to inactivate the Wnt signaling by binding to hARD1 or beta-catenin, which may contribute to the hypoxia-induced growth arrest of tumor cells. (PMID:18593917)
• ARD1A is implicated in cellular proliferation and carcinogenesis. (PMID:18794801)
• This review focuses on the enzymatic and biological activities of human ARD1, the reduction of which negatively affects cell growth and may be a potential cancer drug target. (PMID:18991565)
• accumulation of hARD1 protein may be related to carcinogenesis of various types of cancer. (PMID:19287988)
• ARD1 is indeed a bona fide substrate of IKKbeta. (PMID:19716809)
• hARD1 is a bona fide regulator of MLCK, and hARD1 plays a crucial role in the balance between tumor cell migration and stasis (PMID:19826488)
• Results suggest that hARD1 might play an important role in breast cancer carcinogenesis. (PMID:19909012)
• ARD1 functions as an inhibitor of the mTOR pathway and that dysregulation of the ARD1-TSC2-mTOR axis may contribute to cancer development (PMID:20145209)
• Data indicate that the physical interaction between HYPK and NatA Naa10/15 seems to be of functional importance both for huntingtin aggregation and for N-terminal acetylation. (PMID:20154145)
• Results show that hARD1 autoacetylation is critical for its activation and its ability to stimulate cancer cell proliferation and tumorigenesis. (PMID:20501853)
• interaction between hNaa10p and DNMT1 was required for E-cadherin silencing through promoter CpG methylation, and E-cadherin repression contributed to the oncogenic effects of hNaa10p. (PMID:20592467)
• These results indicate that ARD1A is a novel tumor-associated antigen and a potential prognostic factor for colon cancer. (PMID:20639454)
• suggest that Naa10p functions as a tumor metastasis suppressor by disrupting the migratory complex, PIX-GIT- Paxillin, in cancer cells (PMID:21295525)
• N(alpha)-acetyltransferase 10 may function as a post-translational actin N(alpha)-acetyltransferase. (PMID:21383206)
• A reduction in acetylation by hNaa10p causes lethal X-linked disorder of infancy. (PMID:21700266)
• Arrest-defective protein 1 homolog A (ARD1) in combination with SNCG/Hiwi/PRL-3 may lead to a poor outcome in patients with or without lymph node metastatic colon cancer. (PMID:22261620)
• ARD1 functions as a unique AR regulator in prostate cancer cells. (PMID:22315407)
• study revealed a novel mechanism controlling MCL1 expression, in which Naa10p and RelA/p65 synergistically interact with MCL1 promoter region and promote MCL1 transcription (PMID:22496479)
• These data indicate that the interaction between ARD1 and RIP1 plays an important role in the DNA damage-induced NF-kappaB activation, and that the acetyltransferase activity of ARD1 and its localization in to the nucleus are involved in such stress response. (PMID:22580278)
• Protein N-terminal acetyltransferases (NATs), including Naa10, act as N-terminal propionyltransferases. (PMID:23043182)
• The expression level of NAA10 is inversely correlated with that of MMP-9 in breast cancer samples. (PMID:23550278)
• Development of the first specific NAT-inhibitors, including inhibitors targeting Naa10. (PMID:23557624)
• Naa10p suppresses 28S proteasome activity through interaction with PA28beta. (PMID:23624078)
• Study describes a Saccharomyces cerevisiae model developed by introducing the human wild-type (wt) or mutant NatA complex into yeast lacking NatA (NatA-Delta). The wt human NatA complex phenotypically complemented the NatA-Delta strain, whereas only a partial rescue was observed for the Ogden mutant NatA complex suggesting that hNaa10 S37P is only partially functional in vivo. (PMID:24408909)
• The study concludes that the NAA10 mutation is the cause of Lenz microphthalmia syndrome in a family, likely through the dysregulation of the retinoic acid signalling pathway. (PMID:24431331)
• Naa10p inhibits the metastasis of breast cancer cells by targeting STAT5a. (PMID:24925029)
• De novo missense mutations in the NAA10 gene cause severe non-syndromic developmental delay in males and females (PMID:25099252)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	naa10	ENSDARG00000071060
mus_musculus	Naa10	ENSMUSG00000031388
rattus_norvegicus	Naa10	ENSRNOG00000060063
drosophila_melanogaster	vnc	FBGN0263251
caenorhabditis_elegans		WBGENE00000923

Paralogs (4): NAA50 (ENSG00000121579), NAA30 (ENSG00000139977), NAA11 (ENSG00000156269), NAA20 (ENSG00000173418)

Protein

Protein identifiers

N-alpha-acetyltransferase 10 — P41227 (reviewed: P41227)

Alternative names: N-terminal acetyltransferase complex ARD1 subunit homolog A, NatA catalytic subunit Naa10

All UniProt accessions (5): P41227, A8MWP7, C9JN83, C9JW55, F8W808

UniProt curated annotations — full annotation on UniProt →

Function. Catalytic subunit of N-terminal acetyltransferase complexes which display alpha (N-terminal) acetyltransferase activity. Acetylates amino termini that are devoid of initiator methionine. The alpha (N-terminal) acetyltransferase activity may be important for vascular, hematopoietic and neuronal growth and development. Without NAA15, displays epsilon (internal) acetyltransferase activity towards HIF1A, thereby promoting its degradation. Represses MYLK kinase activity by acetylation, and thus represses tumor cell migration. Acetylates, and stabilizes TSC2, thereby repressing mTOR activity and suppressing cancer development. Acetylates HSPA1A and HSPA1B at ‘Lys-77’ which enhances its chaperone activity and leads to preferential binding to co-chaperone HOPX. Acetylates HIST1H4A. Acts as a negative regulator of sister chromatid cohesion during mitosis.

Subunit / interactions. Component of the N-terminal acetyltransferase A complex (also called the NatA complex) composed of NAA10 and NAA15. Within the complex interacts with NAA15. Component of the N-terminal acetyltransferase A (NatA)/HYPK complex at least composed of NAA10, NAA15 and HYPK, which has N-terminal acetyltransferase activity. In complex with NAA15, interacts with HYPK. Component of the N-terminal acetyltransferase E (NatE) complex at least composed of NAA10, NAA15 and NAA50. Within the complex interacts with NAA15; the interaction is required for binding to NAAT50. Interacts with NAAT50. The interaction of the NatA complex with NAA50 reduces the acetylation activity of the NatA complex. Component of the N-terminal acetyltransferase E (NatE)/HYPK complex at least composed of NAA10, NAA15, NAA50 and HYPK. In complex with NAA15, interacts with HYPK; the interaction with HYPK reduces the capacity of the NatA complex to interact with NAA50. Interacts with HIF1A (via its ODD domain); the interaction increases HIF1A protein stability during normoxia, an down-regulates it when induced by hypoxia. Interacts with the ribosome. Binds to MYLK. Interacts with NAA16. Interacts (via its C-terminal domain) with TSC2, leading to its acetylation. Interacts with IKBKB. Interacts with HSPA1A and HSPA1B leading to its acetylation.

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Ubiquitous.

Post-translational modifications. Cleaved by caspases during apoptosis. Phosphorylation by IKBKB/IKKB at Ser-209 promotes its proteasome-mediated degradation. Autoacetylated at Lys-136 which stimulates its catalytic activity.

Disease relevance. N-terminal acetyltransferase deficiency (NATD) [MIM:300855] An enzymatic deficiency resulting in postnatal growth failure with severe delays and dysmorphic features. It is clinically characterized by wrinkled forehead, prominent eyes, widely opened anterior and posterior fontanels, downsloping palpebral fissures, thickened lids, large ears, flared nares, hypoplastic alae, short columella, protruding upper lip, and microretrognathia. There are also delayed closing of fontanels and broad great toes. Skin is characterized by redundancy or laxity with minimal subcutaneous fat, cutaneous capillary malformations, and very fine hair and eyebrows. Death results from cardiogenic shock following arrhythmia. The disease is caused by variants affecting the gene represented in this entry. Microphthalmia, syndromic, 1 (MCOPS1) [MIM:309800] A rare syndrome defined by the canonical features of unilateral or bilateral microphthalmia or anophthalmia and defects in the skeletal and genitourinary systems. Microphthalmia is a disorder of eye formation, ranging from small size of a single eye to complete bilateral absence of ocular tissues (anophthalmia). In many cases, microphthalmia/anophthalmia occurs in association with syndromes that include non-ocular abnormalities. Anomalies of the digits, teeth, and ears are hallmarks of MCOPS1. Intellectual disability ranges from mild to severe, with self-mutilating behaviors and seizures in severely affected MCOPS1 individuals. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the acetyltransferase family. ARD1 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P41227-1	1	yes
P41227-2	2

RefSeq proteins (3): NP_001243048, NP_001243049, NP_003482* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000182	GNAT_dom	Domain
IPR016181	Acyl_CoA_acyltransferase	Homologous_superfamily
IPR045047	Ard1-like	Family

Pfam: PF00583

Enzyme classification (BRENDA):

• EC 2.3.1.255 — N-terminal amino-acid Nalpha-acetyltransferase NatA (BRENDA: 13 organisms, 96 substrates, 5 inhibitors, 24 Km, 23 kcat entries)
• EC 2.3.1.258 — N-terminal methionine Nalpha-acetyltransferase NatE (BRENDA: 8 organisms, 79 substrates, 9 inhibitors, 25 Km, 15 kcat entries)
• EC 2.3.1.48 — histone acetyltransferase (BRENDA: 41 organisms, 681 substrates, 1134 inhibitors, 140 Km, 96 kcat entries)

Substrate kinetics (BRENDA)

42 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ACETYL-COA	0.0002–0.046	51
HISTONE H3	0.007–2.09	23
SASEAGVRWGRPVGRRRRP	0.3–1.85	19
HISTONE H4	—	11
HISTONE H4 PEPTIDE	0.0208–0.197	7
MVNALE	0.0153–0.1469	6
HISTONE	0.075–1.4	6
ACETYL-COA	0.196–0.6717	4
HISTONE H3 TAIL PEPTIDE	0.044–0.112	4
PICCOLONUA4 PEPTIDE	0.135–0.372	4
3-AZIDOPROPIONYL-COA	0.0002–0.0086	3
4-PENTYNOYL-COA	0.0009–0.0859	3
SPERMIDINE	0.18–0.27	3
ACETYL-COA	0.005–0.0069	2
N-TERMINAL-L-METHIONYL-L-LEUCYL-GLYCYL-L-PROLINE	0.0962–0.8315	2

Catalyzed reactions (Rhea), 6 shown:

• N-terminal glycyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetylglycyl-[protein] + CoA + H(+) (RHEA:50496)
• N-terminal L-alanyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-alanyl-[protein] + CoA + H(+) (RHEA:50500)
• N-terminal L-seryl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-seryl-[protein] + CoA + H(+) (RHEA:50504)
• N-terminal L-valyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-valyl-[protein] + CoA + H(+) (RHEA:50508)
• N-terminal L-cysteinyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-cysteinyl-[protein] + CoA + H(+) (RHEA:50512)
• N-terminal L-threonyl-[protein] + acetyl-CoA = N-terminal N(alpha)-acetyl-L-threonyl-[protein] + CoA + H(+) (RHEA:50516)

UniProt features (37 total): strand 9, modified residue 8, helix 8, sequence variant 3, splice variant 2, mutagenesis site 2, region of interest 2, chain 1, domain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

12 structures.

PDB	Method	Resolution (Å)
9FPZ	ELECTRON MICROSCOPY	2.69
6C9M	X-RAY DIFFRACTION	2.8
9F1B	ELECTRON MICROSCOPY	3.01
6PPL	ELECTRON MICROSCOPY	3.02
6C95	X-RAY DIFFRACTION	3.15
9F1D	ELECTRON MICROSCOPY	3.26
9QQB	ELECTRON MICROSCOPY	3.43
9F1C	ELECTRON MICROSCOPY	3.78
9GJ6	ELECTRON MICROSCOPY	3.91
6PW9	ELECTRON MICROSCOPY	4.03
9GJ5	ELECTRON MICROSCOPY	4.61
9FQ0	ELECTRON MICROSCOPY	4.67

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P41227-F1	81.99	0.71

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (8): 209, 213, 216, 1, 136, 182, 186, 205

Mutagenesis-validated functional residues (2):

Position	Phenotype
136	loss of its ability to acetylate hspa1a and hspa1b.
209	abolishes phosphorylation by ikkb and reduces cell growth.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 571 (showing top): GOBP_CHROMOSOME_ORGANIZATION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, PUJANA_CHEK2_PCC_NETWORK, GOBP_PROTEIN_MATURATION, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CELL_CYCLE, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_SISTER_CHROMATID_COHESION, GOBP_REGULATION_OF_CELL_CYCLE, MORF_BUB3, GOBP_NEGATIVE_REGULATION_OF_CHROMOSOME_ORGANIZATION, GOBP_PROTEIN_FOLDING, MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_UP, WANG_TARGETS_OF_MLL_CBP_FUSION_DN

GO Biological Process (7): protein maturation (GO:0051604), positive regulation of protein refolding (GO:1904592), negative regulation of maintenance of mitotic sister chromatid cohesion, centromeric (GO:2000719), protein acetylation (GO:0006473), N-terminal protein amino acid acetylation (GO:0006474), internal protein amino acid acetylation (GO:0006475), chromosome organization (GO:0051276)

GO Molecular Function (11): protein-N-terminal amino-acid acetyltransferase activity (GO:0004596), N-acetyltransferase activity (GO:0008080), protein-N-terminal-alanine acetyltransferase activity (GO:0008999), protein N-terminal-serine acetyltransferase activity (GO:1990189), protein-N-terminal-glutamate acetyltransferase activity (GO:1990190), protein binding (GO:0005515), acetyltransferase activity (GO:0016407), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), acyltransferase activity, transferring groups other than amino-acyl groups (GO:0016747), ribosome binding (GO:0043022)

GO Cellular Component (6): nucleus (GO:0005634), nucleolus (GO:0005730), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020), NatA complex (GO:0031415)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein-N-terminal amino-acid acetyltransferase activity	3
cellular anatomical structure	3
protein acetylation	2
gene expression	1
protein metabolic process	1
protein refolding	1
regulation of protein refolding	1
positive regulation of protein folding	1
negative regulation of maintenance of mitotic sister chromatid cohesion	1
maintenance of mitotic sister chromatid cohesion, centromeric	1
regulation of maintenance of mitotic sister chromatid cohesion, centromeric	1
protein acylation	1
N-terminal protein amino acid modification	1
protein maturation	1
organelle organization	1
protein N-acetyltransferase activity	1
acetyltransferase activity	1
binding	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
catalytic activity	1
transferase activity	1
acyltransferase activity	1
ribonucleoprotein complex binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular membraneless organelle	1
intracellular anatomical structure	1
cytoplasm	1
N-terminal protein acetyltransferase complex	1

Protein interactions and networks

STRING

2043 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NAA10	NAA15	Q9BXJ9	999
NAA10	NAA50	Q9GZZ1	981
NAA10	HYPK	Q9NX55	977
NAA10	NAA60	Q9H7X0	903
NAA10	NAA16	Q6N069	899
NAA10	RENBP	P51606	865
NAA10	NAA25	Q14CX7	823
NAA10	NAA40	Q86UY6	810
NAA10	ESCO1	Q5FWF5	794
NAA10	ESCO2	Q56NI9	793
NAA10	NAA80	Q93015	774
NAA10	ICE2	Q659A1	763
NAA10	AVPR2	P30518	748
NAA10	NAA35	Q5VZE5	742
NAA10	L1CAM	P32004	741

IntAct

279 interactions, top by confidence:

A	B	Type	Score
NAA15	NAA10	psi-mi:“MI:0914”(association)	0.840
NAA10	NAA15	psi-mi:“MI:0915”(physical association)	0.840
NAA10	NAA15	psi-mi:“MI:0403”(colocalization)	0.840
CALCOCO2	NAA10	psi-mi:“MI:0915”(physical association)	0.780
KIFAP3	NAA10	psi-mi:“MI:0915”(physical association)	0.780
NAA10	CALCOCO2	psi-mi:“MI:0915”(physical association)	0.780
NAA10	KIFAP3	psi-mi:“MI:0915”(physical association)	0.780
PDE4DIP	NAA10	psi-mi:“MI:0915”(physical association)	0.740
NAA10	PDE4DIP	psi-mi:“MI:0915”(physical association)	0.740
ZBTB14	NAA10	psi-mi:“MI:0915”(physical association)	0.720
NAA10	ZBTB14	psi-mi:“MI:0915”(physical association)	0.720
NAA10	CREBRF	psi-mi:“MI:0915”(physical association)	0.670
NAA10	CDCA5	psi-mi:“MI:0915”(physical association)	0.670
NAA10	SNX33	psi-mi:“MI:0915”(physical association)	0.670
NAA10	HIF1A	psi-mi:“MI:0915”(physical association)	0.670
NAA10	DDIT4L	psi-mi:“MI:0915”(physical association)	0.600
NAA10	NOXA1	psi-mi:“MI:0915”(physical association)	0.600
DDIT4L	NAA10	psi-mi:“MI:0915”(physical association)	0.600

BioGRID (257): NAA10 (Two-hybrid), NAA10 (Two-hybrid), PDE4DIP (Two-hybrid), CALCOCO2 (Two-hybrid), RBCK1 (Two-hybrid), EHMT2 (Two-hybrid), KIFAP3 (Two-hybrid), BCOR (Two-hybrid), CEP44 (Two-hybrid), FIP1L1 (Two-hybrid), RAB3IP (Two-hybrid), SSX2IP (Two-hybrid), KRTAP10-7 (Two-hybrid), KRTAP10-5 (Two-hybrid), KRTAP10-3 (Two-hybrid)

ESM2 similar proteins: A0A2R8QFQ6, A4IFE4, A9X1D0, B0VX69, B5FW36, C1FXW2, D1LYT2, D3Z7P3, G3MWR8, G3V6U9, O13016, O46411, O88508, O94925, O95544, P13264, P18031, P18507, P20417, P21548, P22723, P35790, P35821, P41227, P47870, P58058, Q01134, Q0VAM2, Q14722, Q1LZ53, Q2KI14, Q3ULA2, Q3UX61, Q4V8K3, Q4W5Z4, Q5RC04, Q5SRY7, Q5ZML9, Q6ZPR4, Q7RTP6

Diamond homologs: O61219, O74457, P07347, P36416, P41227, P61599, P61600, Q03503, Q05885, Q06504, Q2KI14, Q2PFM2, Q3UX61, Q4JBG0, Q4V8K3, Q58925, Q58ED9, Q6P632, Q7ZXR3, Q8SSN5, Q976C3, Q980R9, Q9BSU3, Q9FKI4, Q9QY36, Q9UTI3, A1ADU8, O74311, O80438, P63420, P63421, P63422, P63423, P63424, P76539, Q0IHH1, Q0T275, Q0TF35, Q147X3, Q1R8T7

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
NAA10	“form complex”	NatA	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

231 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	14
Likely pathogenic	14
Uncertain significance	65
Likely benign	44
Benign	27

Top pathogenic / likely-pathogenic (28)

Variant ID	HGVS	Classification
102423	NM_003491.4(NAA10):c.471+2T>A	Pathogenic
1028122	NM_003491.4(NAA10):c.472-2A>C	Pathogenic
139643	NM_003491.4(NAA10):c.319G>T (p.Val107Phe)	Pathogenic
208664	NM_003491.4(NAA10):c.247C>T (p.Arg83Cys)	Pathogenic
218104	NM_003491.4(NAA10):c.128A>C (p.Tyr43Ser)	Pathogenic
236258	NM_003491.4(NAA10):c.384T>A (p.Phe128Leu)	Pathogenic
280237	NM_003491.4(NAA10):c.384T>G (p.Phe128Leu)	Pathogenic
29927	NM_003491.4(NAA10):c.109T>C (p.Ser37Pro)	Pathogenic
3340772	NM_003491.4(NAA10):c.226G>A (p.Ala76Thr)	Pathogenic
3766065	NM_003491.4(NAA10):c.50G>A (p.Cys17Tyr)	Pathogenic
520542	NM_003491.4(NAA10):c.332T>G (p.Val111Gly)	Pathogenic
561061	NM_003491.4(NAA10):c.494_495del (p.Lys165fs)	Pathogenic
640994	NC_000023.10:g.(?153137587)(153363142_?)dup	Pathogenic
973227	NM_003491.4(NAA10):c.257T>G (p.Leu86Arg)	Pathogenic
1211059	NM_003491.4(NAA10):c.236G>A (p.Arg79His)	Likely pathogenic
1299213	NM_003491.4(NAA10):c.376C>G (p.Leu126Val)	Likely pathogenic
1300802	NM_003491.4(NAA10):c.49T>G (p.Cys17Gly)	Likely pathogenic
1327568	NM_003491.4(NAA10):c.469G>A (p.Glu157Lys)	Likely pathogenic
1705306	NM_003491.4(NAA10):c.128A>G (p.Tyr43Cys)	Likely pathogenic
3376962	NM_003491.4(NAA10):c.387-1G>A	Likely pathogenic
372842	NM_003491.4(NAA10):c.339G>T (p.Lys113Asn)	Likely pathogenic
375388	NM_003491.4(NAA10):c.215T>C (p.Ile72Thr)	Likely pathogenic
431708	NM_003491.4(NAA10):c.361C>G (p.Leu121Val)	Likely pathogenic
432646	NM_003491.4(NAA10):c.92A>G (p.Tyr31Cys)	Likely pathogenic
4681857	NM_003491.4(NAA10):c.445C>G (p.Arg149Gly)	Likely pathogenic
617463	NM_003491.4(NAA10):c.*43A>G	Likely pathogenic
637034	NM_003491.4(NAA10):c.115C>A (p.Pro39Thr)	Likely pathogenic
804121	NM_003491.4(NAA10):c.377T>G (p.Leu126Arg)	Likely pathogenic

SpliceAI

1122 predictions. Top by Δscore:

Variant	Effect	Δscore
X:153930231:C:CT	acceptor_gain	1.0000
X:153930239:C:CT	acceptor_gain	1.0000
X:153930240:A:T	acceptor_gain	1.0000
X:153930757:GCTTA:G	donor_loss	1.0000
X:153930759:TTACC:T	donor_loss	1.0000
X:153930760:TA:T	donor_loss	1.0000
X:153930761:A:AC	donor_gain	1.0000
X:153930761:ACCTC:A	donor_loss	1.0000
X:153930762:C:A	donor_loss	1.0000
X:153930762:C:CC	donor_gain	1.0000
X:153930762:CCT:C	donor_gain	1.0000
X:153930843:TGATC:T	acceptor_gain	1.0000
X:153930846:TC:T	acceptor_gain	1.0000
X:153930847:CC:C	acceptor_gain	1.0000
X:153930848:C:CA	acceptor_loss	1.0000
X:153930848:C:CC	acceptor_gain	1.0000
X:153930849:T:G	acceptor_loss	1.0000
X:153932116:C:CC	acceptor_gain	1.0000
X:153932297:C:A	donor_gain	1.0000
X:153932311:T:TA	donor_gain	1.0000
X:153932317:T:TA	donor_gain	1.0000
X:153932320:T:A	donor_gain	1.0000
X:153932341:A:AC	donor_gain	1.0000
X:153932427:ACAGC:A	acceptor_gain	1.0000
X:153932428:CAGC:C	acceptor_gain	1.0000
X:153932428:CAGCC:C	acceptor_gain	1.0000
X:153932429:AGC:A	acceptor_gain	1.0000
X:153932430:GC:G	acceptor_gain	1.0000
X:153932431:CC:C	acceptor_gain	1.0000
X:153932432:C:A	acceptor_loss	1.0000

AlphaMissense

1561 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:153930782:A:G	L151P	1.000
X:153930788:C:G	R149P	1.000
X:153930793:C:A	M147I	1.000
X:153930793:C:G	M147I	1.000
X:153930793:C:T	M147I	1.000
X:153930794:A:C	M147R	1.000
X:153930794:A:G	M147T	1.000
X:153930794:A:T	M147K	1.000
X:153930798:C:G	A146P	1.000
X:153930801:A:C	Y145D	1.000
X:153930803:G:A	A144V	1.000
X:153930803:G:T	A144D	1.000
X:153930804:C:G	A144P	1.000
X:153930804:C:T	A144T	1.000
X:153930806:T:A	D143V	1.000
X:153930807:C:G	D143H	1.000
X:153930808:C:A	E142D	1.000
X:153930808:C:G	E142D	1.000
X:153930809:T:A	E142V	1.000
X:153930810:C:T	E142K	1.000
X:153930813:C:A	G141W	1.000
X:153930814:A:C	D140E	1.000
X:153930814:A:T	D140E	1.000
X:153930815:T:A	D140V	1.000
X:153930815:T:G	D140A	1.000
X:153930816:C:A	D140Y	1.000
X:153930816:C:G	D140H	1.000
X:153930818:G:T	A139E	1.000
X:153930819:C:G	A139P	1.000
X:153930821:T:C	Y138C	1.000

dbSNP variants (sampled 300 via entrez): RS1000986627 (X:153936747 C>T), RS1001424554 (X:153932816 C>A), RS1002425512 (X:153934657 G>C), RS1003101587 (X:153931010 G>A), RS10046980 (X:153934130 C>A,T), RS1004954870 (X:153932494 C>A,T), RS1005415418 (X:153932876 T>C,G), RS1005542383 (X:153929540 G>C,T), RS1006071227 (X:153929124 C>T), RS1007349241 (X:153936399 G>C), RS1007463744 (X:153935989 C>T), RS1008183008 (X:153931519 A>G), RS1008483395 (X:153931833 C>T), RS1009346 (X:153931231 G>C), RS1009347 (X:153931408 C>T)

Disease associations

OMIM: gene MIM:300013 | disease phenotypes: MIM:309800, MIM:300855, MIM:148840, MIM:300100, MIM:156200, MIM:300673

GenCC curated gene-disease

Disease	Classification	Inheritance
Ogden syndrome	Definitive	X-linked
NAA10-related syndrome	Definitive	X-linked
microphthalmia, syndromic 1	Moderate	X-linked
microphthalmia, Lenz type	Supportive	X-linked

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
NAA10-related syndrome	Definitive	XL

Mondo (10): microphthalmia, syndromic 1 (MONDO:0010671), Ogden syndrome (MONDO:0010457), Kleine-Levin syndrome (MONDO:0007863), intellectual disability (MONDO:0001071), NAA10-related syndrome (MONDO:0100124), adrenoleukodystrophy (MONDO:0018544), intellectual disability, autosomal dominant (MONDO:0100172), severe neonatal-onset encephalopathy with microcephaly (MONDO:0010397), neurodevelopmental disorder (MONDO:0700092), microphthalmia, Lenz type (MONDO:0018924)

Orphanet (7): Microphthalmia, Lenz type (Orphanet:568), Microphthalmia-ankyloblepharon-intellectual disability syndrome (Orphanet:85275), Ogden syndrome (Orphanet:276432), Kleine-Levin syndrome (Orphanet:33543), X-linked adrenoleukodystrophy (Orphanet:43), MECP2-related severe neonatal encephalopathy (Orphanet:209370), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

216 total (30 of 216 shown, HPO-id order):

HPO	Term
HP:0000023	Inguinal hernia
HP:0000028	Cryptorchidism
HP:0000034	Hydrocele testis
HP:0000047	Hypospadias
HP:0000072	Hydroureter
HP:0000089	Renal hypoplasia
HP:0000105	Enlarged kidney
HP:0000113	Polycystic kidney dysplasia
HP:0000126	Hydronephrosis
HP:0000164	Abnormality of the dentition
HP:0000189	Narrow palate
HP:0000202	Orofacial cleft
HP:0000204	Cleft upper lip
HP:0000215	Thick upper lip vermilion
HP:0000218	High palate
HP:0000219	Thin upper lip vermilion
HP:0000233	Thin vermilion border
HP:0000252	Microcephaly
HP:0000260	Wide anterior fontanel
HP:0000270	Delayed cranial suture closure
HP:0000280	Coarse facial features
HP:0000286	Epicanthus
HP:0000290	Abnormal forehead morphology
HP:0000308	Microretrognathia
HP:0000316	Hypertelorism
HP:0000322	Short philtrum
HP:0000337	Broad forehead
HP:0000341	Narrow forehead
HP:0000343	Long philtrum
HP:0000347	Micrognathia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003155_27	Systemic lupus erythematosus	2.000000e-15

MeSH disease descriptors (7)

Descriptor	Name	Tree numbers
D000326	Adrenoleukodystrophy	C10.228.140.163.100.084; C10.228.140.163.100.362.250; C10.228.140.695.625.250; C10.314.400.250; C10.597.606.360.455.124; C16.320.322.500.124; C16.320.400.525.124; C16.320.565.189.084; C16.320.565.189.362.250; C16.320.565.663.100; C18.452.132.100.084; C18.452.132.100.362.250; C18.452.648.189.084; C18.452.648.189.362.250; C18.452.648.663.100; C19.053.500.270
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D017593	Kleine-Levin Syndrome	C10.886.425.800.200.500; F03.870.400.800.200.500
D065886	Neurodevelopmental Disorders	F03.625
C566878	Encephalopathy, Neonatal Severe, Due To Mecp2 Mutations (supp.)
C537464	Microphthalmia, syndromic 1 (supp.)
C536107	N acetyltransferase deficiency (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4630819 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.09	Kd	817.3	nM	CHEMBL5653589
6.09	ED50	817.3	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 4 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148814: Binding affinity to human NAA10 incubated for 45 mins by Kinobead based pull down assay	kd	0.8173	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	4
bisphenol A	affects expression, decreases expression	3
sodium arsenite	affects cotreatment, decreases expression, increases abundance	3
Tretinoin	affects cotreatment, decreases expression, increases expression	3
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, affects expression	2
Ozone	affects cotreatment, increases oxidation, increases abundance, affects expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
FR900359	decreases phosphorylation	1
moringin	affects cotreatment, increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
decabromobiphenyl ether	increases expression	1
arsenite	affects binding, increases reaction	1
cobaltous chloride	decreases expression	1
tanshinone	increases expression	1
nickel chloride	decreases expression	1
coumarin	affects phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
2-palmitoylglycerol	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases methylation	1
bisphenol AF	increases expression	1
Temozolomide	increases expression	1
Sunitinib	decreases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Arsenic	decreases expression, increases abundance	1
Vehicle Emissions	increases abundance, decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4618912	Binding	Binding affinity to Naa10 in human A549 cell lysates assessed as thermal stabilization of protein at 50 uM after 30 mins followed by heating at 40 to 64 degC for 3 mins by immunoblot-based CESTA	Characterization of Specific N-α-Acetyltransferase 50 (Naa50) Inhibitors Identified Using a DNA Encoded Library. — ACS Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 telomerase immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C0QI	S37P-hTERT	Telomerase immortalized cell line	Male

Clinical trials (associated diseases)

200 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT01793168	Not specified	RECRUITING	Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
NCT02337023	Not specified	COMPLETED	Brain Scintigraphy in Normal Versus Kleine-Levin Syndrome Subjects
NCT03754348	Not specified	COMPLETED	Microglial Activation in Narcolepsy Type 1 and Kleine-Levin Syndrome: Positron Emission Tomography (PET) Study in [18F] DPA-714
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)